Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/23/23
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023GlobeNewsWire • 03/14/23
Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?Zacks Investment Research • 03/09/23
Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/06/23
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/06/23
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS ActivityGlobeNewsWire • 03/05/23
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business UpdatesGlobeNewsWire • 02/27/23
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS MutationsGlobeNewsWire • 11/28/22
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/22
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/10/22
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITCGlobeNewsWire • 11/10/22
These Are the Five Best and Worst Performing Small-cap Stocks in September 202224/7 Wall Street • 10/22/22
These Were The Five Best And Worst Performing Healthcare Stocks In September 202224/7 Wall Street • 10/17/22
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 10/05/22
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS MutationsGlobeNewsWire • 09/30/22
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?Zacks Investment Research • 09/12/22
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS MutationsGlobeNewsWire • 09/02/22